Literature DB >> 19412574

The differentiation of human placenta-derived mesenchymal stem cells into dopaminergic cells in vitro.

Li Chen1, Dong-Mei He, Yuan Zhang.   

Abstract

Mesenchymal stem cells (MSCs) constitute an interesting cellular source to promote brain regeneration after Parkinson's disease. MSCs have significant advantages over other stem cell types, and greater potential for immediate clinical application. The aim of this study was to investigate whether MSCs from the human placenta could be induced to differentiate into dopaminergic cells. MSCs from the human placenta were isolated by digestion and density gradient fractionation, and their cell surface glycoproteins were analyzed by flow cytometry. These MSCs were cultured under conditions promoting differetiation into adipocytes and osteoblasts. Using a cocktail that includes basic fibroblast growth factor (bFGF), all trans retinoic acid (RA), ascorbic acid (AA) and 3-isobutyl-1-methylxanthine (IBMX), the MSCs were induced in vitro to become dopamine (DA) neurons. Then, the expression of the mRNA for the Nestin and tyrosine hydroxylase (TH) genes was assayed via RT-PCR. The expression of the Nestin, dopamine transporter (DAT), neuronal nuclear protein (NeuN) and TH proteins was determined via immunofluorescence. The synthesized and secreted DA was determined via ELISA. We found that MSCs from the human placenta exhibited a fibroblastoid morphology. Flow cytometric analyses showed that the MSCs were positive for CD44 and CD29, and negative for CD34, CD45, CD106 and HLA-DR. Moreover, they could be induced into adipocytes and osteocytes. When the MSCs were induced with bFGF, RA, AA and IBMX, they showed a change in morphology to that of neuronal-like cells. The induced cells expressed Nestin and TH mRNA, and the Nestin, DAT, NeuN and TH proteins, and synthesized and secreted DA. Our results suggest that MSCs from the human placenta have the ability to differentiate into dopaminergic cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19412574      PMCID: PMC6275933          DOI: 10.2478/s11658-009-0015-3

Source DB:  PubMed          Journal:  Cell Mol Biol Lett        ISSN: 1425-8153            Impact factor:   5.787


  20 in total

Review 1.  Regenerative therapy for neuronal diseases with transplantation of somatic stem cells.

Authors:  Hiroshi Kanno
Journal:  World J Stem Cells       Date:  2013-10-26       Impact factor: 5.326

Review 2.  In vitro and in vivo neurogenic potential of mesenchymal stem cells isolated from different sources.

Authors:  Ramyani Taran; Murali Krishna Mamidi; Gurbind Singh; Susmita Dutta; Ishwar S Parhar; John P John; Ramesh Bhonde; Rajarshi Pal; Anjan Kumar Das
Journal:  J Biosci       Date:  2014-03       Impact factor: 1.826

3.  Efficient Generation of Functionally Active Spinal Cord Neurons from Spermatogonial Stem Cells.

Authors:  Hao Yang; Cuicui Liu; Bo Chen; Jing An; Rui Zhang; Qian Zhang; Jingjing Zhao; Baorong He; Ding-Jun Hao
Journal:  Mol Neurobiol       Date:  2016-08-26       Impact factor: 5.590

4.  Regenerative medicine for Parkinson's disease using differentiated nerve cells derived from human buccal fat pad stem cells.

Authors:  Haruka Takahashi; Hiroshi Ishikawa; Akira Tanaka
Journal:  Hum Cell       Date:  2017-02-16       Impact factor: 4.174

Review 5.  Eminent Sources of Adult Mesenchymal Stem Cells and Their Therapeutic Imminence.

Authors:  Dannie Macrin; Joel P Joseph; Aruthra Arumugam Pillai; Arikketh Devi
Journal:  Stem Cell Rev Rep       Date:  2017-12       Impact factor: 5.739

6.  Bone marrow-derived mesenchymal stem cells improve post-ischemia neurological function in rats via the PI3K/AKT/GSK-3β/CRMP-2 pathway.

Authors:  Xiaohui Lin; Hongbin Chen; Manli Chen; Ting Li; Yongxing Lai; Longzai Lin; Peiqiang Lin; Ji Liu; Yixian Zhang; Ronghua Chen; Houwei Du; Xinhong Jiang; Nan Liu
Journal:  Mol Cell Biochem       Date:  2021-02-09       Impact factor: 3.396

Review 7.  Immunosuppressive properties of mesenchymal stem cells.

Authors:  Mohamed Abumaree; Mohammed Al Jumah; Rishika A Pace; Bill Kalionis
Journal:  Stem Cell Rev Rep       Date:  2012-06       Impact factor: 5.739

Review 8.  Progress in stem cell therapy for major human neurological disorders.

Authors:  P L Martínez-Morales; A Revilla; I Ocaña; C González; P Sainz; D McGuire; I Liste
Journal:  Stem Cell Rev Rep       Date:  2013-10       Impact factor: 5.739

Review 9.  Allogenic Use of Human Placenta-Derived Stromal Cells as a Highly Active Subtype of Mesenchymal Stromal Cells for Cell-Based Therapies.

Authors:  Raphael Gorodetsky; Wilhelm K Aicher
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

Review 10.  The immunomodulatory and neuroprotective effects of mesenchymal stem cells (MSCs) in experimental autoimmune encephalomyelitis (EAE): a model of multiple sclerosis (MS).

Authors:  Mohammed A Al Jumah; Mohamed H Abumaree
Journal:  Int J Mol Sci       Date:  2012-07-24       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.